A 64-year-old man with a history of heart failure, type 2 diabetes mellitus, and chronic k… — USMLE Step 3

A 64-year-old man with a history of heart failure, type 2 diabetes mellitus, and chronic kidney disease stage 5 on hemodialysis is brought to the emergency department by his family due to worsening confusion and unsteadiness over the past two days. His medications include lisinopril, amlodipine, and phenytoin, which he takes for a history of remote post-traumatic seizures. Two weeks ago, a routine chemistry panel showed a blood urea nitrogen of $68 \text{ mg/dL}$ , serum creatinine of $5.4 \text{ mg/dL}$ , and serum albumin of $2.2 \text{ g/dL}$ . At that same visit, his total serum phenytoin level was $6.5 \text{ \mu g/mL}$ (therapeutic range: $10-20 \text{ \mu g/mL}$ ). Believing the level was subtherapeutic, the physician increased his daily phenytoin dose. Physical examination today reveals bilateral horizontal nystagmus, wide-based gait ataxia, and dysarthria. A repeat total serum phenytoin level today is $13.5 \text{ \mu g/mL}$ . Which of the following pharmacokinetic principles best explains why the patient is experiencing neurotoxicity despite a total drug level within the normal therapeutic range?

Decreased drug-protein affinity and low albumin increase the unbound fraction of the drugCevap
B
Saturation of hepatic metabolizing enzymes causes a non-linear increase in total drug concentration
C
Concurrent amlodipine use competitively inhibits the cytochrome P450-mediated clearance of the drug
D
Severe renal impairment leads to the accumulation of a renally excreted neurotoxic metabolite
E
Heart failure reduces hepatic blood flow, significantly decreasing the clearance of the drug

Cevap

Decreased drug-protein affinity and low albumin increase the unbound fraction of the drug

The correct answer accurately describes the pharmacokinetic changes in end-stage renal disease (ESRD) and hypoalbuminemia. Phenytoin is approximately 90% protein-bound to serum albumin. In patients with ESRD, uremic toxins competitively inhibit the binding of phenytoin to albumin (decreased affinity). In addition, this patient has significant hypoalbuminemia (

2.2 \text{ g/dL}

), meaning fewer binding sites are available. Both of these factors independently and synergistically increase the unbound (free), pharmacologically active fraction of the drug from ~10% up to 20-30%. As a result, a total serum drug concentration that appears 'subtherapeutic' (such as the initial

6.5 \text{ \mu g/mL}

) or 'normal' (such as the current

13.5 \text{ \mu g/mL}

) can actually contain a highly toxic free drug concentration. The physician inappropriately increased the dose by relying solely on the total drug level without mathematically adjusting it for the patient's albumin and renal status (e.g., using the Winter-Tozer equation) or checking a free phenytoin level.

Adım Adım Çözüm

Identify the patient's clinical presentation and correlate it with the recent medication change.

The patient is presenting with classic signs of phenytoin toxicity (horizontal nystagmus, ataxia, dysarthria) shortly after a dose increase.

Recognizing the toxidrome confirms that the patient is actively experiencing adverse effects from the drug.

Analyze the laboratory data in the context of the drug's properties.

The total serum phenytoin level is

13.5 \text{ \mu g/mL}

(within the normal range of 10-20), but the patient has severe uremia (BUN

68 \text{ mg/dL}

) and hypoalbuminemia (albumin

2.2 \text{ g/dL}

Phenytoin is highly protein-bound, and its active free fraction is significantly affected by circulating albumin levels and renal function.

Apply pharmacokinetic principles to explain the discrepancy between the normal total level and clinical toxicity.

Uremia alters the binding affinity of albumin for the drug, and hypoalbuminemia reduces the total number of binding sites. Both factors increase the free, pharmacologically active fraction of the drug.

Because standard total drug levels measure both bound and unbound drug, a pathological increase in the unbound fraction causes toxicity even when the total concentration remains within the reference range.

Anahtar Kavram

Phenytoin is highly protein-bound, and states of uremia and hypoalbuminemia increase the free (active) fraction of the drug, necessitating dose adjustments based on calculated or measured free levels rather than total levels.

Tahmini Süre:2m 0s

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru